2026-10-10T20:01:58Z https://api.figshare.com/v2/oai

oai:figshare.com:article/32639478 2026-10-01T16:39:44Z portal_1172 item_type_8 month_year_10_2026

Transdermal delivery of pramipexole using microneedle technology for the potential treatment of Parkinson’s disease Mary B McGuckin (24168666) PUREID: 586965723 Parkinson's disease pramipexole microneedle transdermal drug delivery Parkinson's disease is a debilitating neurodegenerative disease primarily impacting neurones responsible for dopamine production within the brain. Pramipexole (PRA) is a dopamine agonist that enhances dopamine neurotransmission, restoring balance and alleviating symptoms. The work presented here shows how transdermal drug delivery, using microneedle (MN) technology, is a promising avenue for addresing issues with current oral treatment of PRA. In vivo investigations confirmed the successful delivery of PRA from dissolving MNs (Cmax = 511.00 ng/mL, Tmax = 4 hrs) and hydrogel-forming MNs (Cmax = 328.30 ng/mL, Tmax = 24 hrs). Notably, both types of MNs sustained PRA plasma levels over a 5-day period compared to 48 hrs following oral administration 2026-10-01T16:39:44Z Text Thesis 10.17034/32639478.v1 https://figshare.com/articles/thesis/Transdermal_delivery_of_pramipexole_using_microneedle_technology_for_the_potential_treatment_of_Parkinson_s_disease/32639478 All Rights Reserved